 BALTIMORE, Feb. 03, 2022 GLOBE NEWSWIRE -- Graybug Vision, Inc. Nasdaq: GRAY, a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced its participation in three upcoming medical and investor conferences: 